Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema.
Carter J PayneUrvi GuptaChristopher M MaatoukBlanche L KuoScott W PerkinsRishi P SinghKatherine E TalcottPublished in: Eye (London, England) (2024)
Many patients experienced improvements in BVA and CST over 12 months of treatment despite receiving less frequent anti-VEGF therapy than recommended in the pivotal trials. The present study showed that extended treatment intervals with bevacizumab were effective in preserving vision of many individuals with high baseline BVA.